News round-up for 1-5 September by DDW Editor Reece Armstrong.

There have been a number of stories this week promoting promising science in the areas of obesity and cardiology, along with a partnership to advance vaccine science.

The top stories

Research programme represents a “new frontier in vaccine science” 

The UK’s University of Oxford, through its strategic partnership with the Ellison Institute of Technology (EIT), has received research funding of £118 ($159.7) million to launch an ambitious new programme of vaccine research.

Read more

FDA approves first BTK inhibitor for immune thrombocytopenia 

The US Food and Drug Administration (FDA) has approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Read more

Microenvironment switches cancer cells to a drug-resistant state  

A new study has revealed that the mechanical environment surrounding a tumour can cause cancer cells to change their behaviour, triggering a switch from rapid growth to a more invasive, drug-resistant state.
Read more

Baxdrostat offers hope for stubborn high blood pressure 

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high despite medication, according to the results of a Phase III clinical trial.

Read more

Novo and Replicate partner on srRNA therapies for obesity

Novo Nordisk and Replicate Bioscience have announced a multi-year research collaboration that will combine Novo’s drug development expertise with Replicate’s srRNA platform to develop new therapeutic candidates for cardiometabolic diseases.

Read more